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Background: Best supportive care only is recommended for pa-
tients with advanced non-small cell lung cancer (NSCLC) with poor
performance status (PS) of Eastern Cooperative Oncology Group 3
or 4. Recently, the possibility of using epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor therapy has been reported
for poor PS patients harboring EGFR mutations.
Methods: We retrospectively analyzed 74 patients with advanced
NSCLC who were treated with first-line gefitinib during hospital-
ization for Eastern Cooperative Oncology Group PS 3 or 4. All
patients were classified according to three clinical parameters:
smoking history, gender, and histology type.
Results: The median age was 64 years (range, 35–86 years). The
proportions of females, never smokers, and adenocarcinoma were
51.4%, 54.1%, and 78.4%, respectively. An overall response rate,
median progression-free survival (PFS), and median overall survival
(OS) was 27.0%, 32 days (95% confidence interval [CI], 22–48
days), and 61 days (95% CI, 7–115 days), respectively. Female
gender, never smoking, and adenocarcinoma histology were strong
predictors of tumor response. Never smoking and adenocarcinoma
were independent predictors of better PFS but not of OS. Seven
patients experienced treatment-related adverse effects of grade 3 to
4, which included anorexia (n  2), pneumonitis (n  4), and
elevated liver enzymes (n  1). Never-smoker females with adeno-
carcinoma exhibited a response rate of 50.0%, median PFS of 130
days (95% CI, 51–209 days), and median OS of 236 days (95% CI,
150–322 days).
Conclusions: Gefitinib may provide clinical benefits for patients
with NSCLC with poor PS who were selected according to clinically
favorable parameters.
Key Words: Non-small cell lung cancer, Performance status, Che-
motherapy, Epidermal growth factor receptor.
(J Thorac Oncol. 2010;5: 361–368)
Poor performance status (PS) is a widely accepted indicatorof poor survival outcomes in advanced non-small cell
lung cancer (NSCLC).1,2 Patients with poor PS constitute a
significant proportion of the lung cancer population followed
in daily oncology practice. In a large population-based reg-
istry, the prevalence of patients with an Eastern Cooperative
Oncology Group (ECOG) PS 3 or 4 was estimated to repre-
sent 12% of all lung cancer patients.3 However, best support-
ive care is the only recommended first treatment available for
these patients.4 Moreover, patients with NSCLC with poor PS
are excluded from prospective clinical trials for anticancer
therapy.
Gefitinib (IRESSA, AstraZeneca) is a molecular-tar-
geted drug that reversibly blocks the tyrosine kinase domain
of the epidermal growth factor receptor (EGFR). Several
clinical trials have demonstrated that this drug is well toler-
ated and has clinical benefits in a subset of patients of East
Asian descent, female gender, never-smoking history, adeno-
carcinoma histologic type, and EGFRmutations.5–8 Recently,
based on its favorable safety profile, this drug has been
evaluated in elderly patients or those with poor PS.9,10 How-
ever, a previous placebo-controlled randomized phase II trial
of Goss et al.9 found no improvement in response rate,
progression-free survival (PFS), or overall survival (OS) after
treatment with gefitinib in 201 chemonaïve patients with
advanced NSCLC with an ECOG PS 2 or 3. Nevertheless,
this earlier study noted that gefitinib significantly improves
PFS compared with placebo in patients with EGFR fluores-
cent in situ hybridization-positive tumors. Furthermore, Inoue
et al.10 showed that in patients with NSCLC with EGFR
mutation-positive tumors, gefitinib treatment resulted in a
long median OS of 17.8 months, despite poor PS (i.e., ECOG
3 or 4). In this genetically selected group, the response rate
was 66% and the median PFS was 6.5 months, which is better
than that reported in the literature.10 The results of these
previous studies suggest that gefitinib may be an effective
therapy for selected populations with good predictors, even
for patients with poor performance.
Although activating EGFR mutations have been known
to be the strongest biologic predictors of the sensitivity of
EGFR tyrosine kinase inhibitors,11–17 screening for the pres-
ence of EGFR mutations, especially in patients with poor PS,
has several practical limitations, including difficulty in ob-
taining sufficient tissue samples for the test, time delay, and
cost. Thus, for these patients, other clinicopathological pa-
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rameters will be more useful in clinical practice than EGFR
mutations. We have accumulated clinical experience regard-
ing the usefulness of clinical predictors of gefitinib treatment
in patients who were unfit for chemotherapy because of poor
PS. Based on this experience, we retrospectively investigated
the efficacy of gefitinib in chemonaïve patients with advanced
NSCLC with an ECOG PS of 3 or 4 by focusing on the role
of clinical predictors in the identification of responders with-
out genetic testing.
PATIENTS AND METHODS
Patients and Data Collection
Using a pharmacy disposition record, we first identified
220 patients with NSCLC who received gefitinib as inpatients
at the National Cancer Center Hospital (Goyang, Republic of
Korea) between July 2003 and March 2009. We assumed that
patients with poor PS would have started the treatment in the
inpatient setting. As shown in Figure 1, we used medical
record reviews to generate the list of patients who met the
following criteria: (1) histologically or cytologically con-
firmed recurrent or metastatic NSCLC, (2) no prior chemo-
therapy, and (3) ECOG PS of 3 or 4 affected by the disease,
which was prospectively documented. Seventy-four patients
were too ill to be treated with standard chemotherapy and
received gefitinib as a first-line treatment for advanced
NSCLC during their hospitalization. Subsequently, we re-
viewed medical records and radiographic images to assess
clinicopathological characteristics, tumor response, and sur-
vival outcomes using a predesigned data collection format.
Treatment and Evaluation
Patients received 250 mg of gefitinib once daily in a
4-week cycle until the onset of disease progression, intoler-
able toxicity, or patient refusal. Imaging studies were per-
formed according to clinical needs. Tumor response was
assessed at 2 to 4 weeks after the first treatment using chest
x-ray and every 8 weeks using computed tomography and
other imaging techniques. Tumor response was determined in
accordance with the guideline established by the Response
Evaluation Criteria in Solid Tumor (RECIST) committee.18
We used the same tumor assessment method in a given
patient for response evaluation. Toxicity was assessed ac-
cording to the National Cancer Institute Common Terminol-
ogy Criteria for Adverse Events, version 3.0.
Statistical Analyses
An analysis of drug efficacy and safety was performed
in all patients who received at least one dose of gefitinib.
However, the response of some patients was not assessable
because of early death before formal radiographic evaluation.
TABLE 1. Patient Baseline Characteristics
Characteristics n (%)
Total 74
Age, yr, median (range) 64 (35–86)
Gender
Female 38 (51.4)
Male 36 (48.6)
Smoking
Never 40 (54.1)
Ever 34 (45.9)
Histology
Adenocarcinoma 58 (78.4)
Squamous cell carcinoma 7 (9.5)
Large cell carcinoma 1 (1.4)
Others 8 (10.8)
Stagea
IIIB 7 (9.5)
IV 67 (90.5)
ECOG
3 48 (64.9)
4 26 (35.1)
Major comorbidity
Any disease 61 (82.4)
Cerebrovascular disease 15 (20.3)
Cardiovascular disease 16 (21.6)
Respiratory disease 20 (27.0)
Diabetes 4 (5.4)
Liver disease 2 (2.7)
Renal disease 4 (5.4)
None 13 (17.6)
Pneumonia requiring antibiotics
Yes 14 (18.9)
No 60 (81.0)
Major cancer-related complications
Respiratory distress 27 (36.5)
Uncontrolled pain 19 (25.7)
Symptomatic CNS metastasis 17 (23.0)
Symptomatic vertebral metastasis 6 (8.1)
SVC syndrome 2 (2.7)
Pericardial tamponade 1 (1.4)
Massive thromboembolism 1 (1.4)
Massive hepatic metastasis 1 (1.4)
a Staging according to the revised International System for Staging Lung Cancer.
ECOG, Eastern Cooperative Group; CNS, central nervous system; SVC, superior
vena cava.FIGURE 1. Patient collection.
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FIGURE 2. Radiologic response to ge-
fitinib in patients with advanced non-
small cell lung cancer (NSCLC) with a
poor performance status (PS) of Eastern
Cooperative Oncology Group (ECOG) 3
or 4. A, Case 1: chest x-ray scans (top)
and computed tomography scans of the
chest (bottom). B, Case 2: positron emis-
sion tomography scans (top) and mag-
netic resonance images of brain (bot-
tom), before and after gefitinib
treatment.
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In this study, an early death was considered as progressive
disease (PD). Response rate represents the percentage of
patients whose best tumor response was complete response or
partial response (PR). Disease control rate is the frequency of
patients whose best tumor response was complete response,
PR, or stable disease at 8 weeks. Pearson’s 2 test or Fisher’s
exact test was used to determine the relationship between
tumor response and categorical variables, where appropriate.
PFS was assessed from the first day of treatment until the first
documentation of disease progression or death. OS was
calculated from the first day of treatment until death or the
most recent follow-up. Survival time was estimated using the
Kaplan-Meier method, and survival difference between
groups was assessed using the log-rank test. The Cox pro-
portional hazards model was used to perform a multivariate
analysis of survival. Two-sided p values less than 0.05 were
considered significant.
RESULTS
Patient and Treatment Characteristics
The baseline characteristics of the assessed patients are
shown in Table 1. The median age was 64 years (range,
35–86 years). The proportions of females, never smokers,
and adenocarcinoma were 51.4%, 54.1%, and 78.4%, respec-
tively. From 2003–2006 to 2007–2009, these percentages
increased from 48.1 to 60.0% (females), 46.7 to 59.1% (never
smokers), and 74.1 to 90.0% (adenocarcinoma). Thirty-eight
patients (51.3%) had serious comorbid illness and 14 (18.9%)
had pneumonia requiring antibiotics. Most patients suffered
from major cancer-related complications, such as respiratory
distress, neurologic dysfunction, or uncontrolled pain.
The median drug cycle administrated per patient was
1.5 cycles (range, 1–19 cycles). The proportion of patients
receiving gefitinib treatment of less than 3 cycles, 3 to 6
cycles, and more than 6 cycles were 86.6%, 18.9%, and
13.5%, respectively. The median treatment duration was 32.5
days (range, 1–539 days). Nine patients (12.2%) had treat-
ment breaks of 1 week or more. Treatment was discontinued
in 70 patients because of PD (n  47), early death (n  8),
treatment-related toxicity (n  7), and other causes (n  8).
After starting gefitinib treatment, 42 patients (56.8%) visited
the outpatient clinic after discharge from inpatient care,
whereas 32 patients died during the initial hospitalization,
either at the National Cancer Center (n 12) or after transfer
to another hospital (n  20).
Tumor Response
Among the 74 patients, the tumor response was PR in
20 patients (27.0%), stable disease in 15 patients (20.3%), PD
in 31 patients (41.9%), and nonevaluable in 8 patients
(10.8%), which yielded a response rate of 27.0% (95%
confidence interval [CI], 16.7–37.3%) and a disease control
rate of 47.3% (95% CI, 35.7–58.9%). Among the 35 patients
who achieved the disease control, 19 (54.2%) received sub-
sequent chemotherapy after gefitinib failure; platinum-based
doublets (n  8), nonplatinum-based doublets (n  5),
docetaxel (n  3), and pemetrexed (n  3). However, there
was no further chemotherapy in the 39 patients who did not
reach the disease control. Tumor response was prompt and
dramatic in gefitinib-responsive patients (Figure 2). The first
case was a 76-year-old female patient with adenocarcinoma
who needed oxygen supply because of severe respiratory
difficulty secondary to hematogenous lung metastasis and
malignant pleural effusion. This patient exhibited a marked
improvement of lung metastasis and pleural effusion at 2
months after gefitinib treatment (Figure 2A). The second case
was a 45-year-old female patient with adenocarcinoma who
initially presented with severe bone pain, generalized weak-
ness, and respiratory difficulty caused by disseminated tumor
burden. This patient achieved a remarkable tumor response at
2 months after gefitinib treatment (Figure 2B).
The response rate was significantly higher in female
patients than in male patients (42.1% versus 11.1%, respec-
tively; p  0.003), in never smokers than in ever smokers
(42.5% versus 8.8%, respectively; p 0.001), and in patients
with adenocarcinoma than in patients with other histologic
types (39.6% versus 18.8%, respectively; p  0.03) (Table
2). Similar differences were observed for the disease control
rate.
Survival Outcome
Survival data were followed up until the end of May
2009, and the median follow-up duration was 52 days (range,
1–704 days). At the time of analysis, 67 patients (90.5%) had
died and 7 (9.5%) had survived; 4 of the survivors were on
gefitinib treatment, 2 had second-line chemotherapy, and 1
was on supportive care. The median PFS and OS were 32
days (95% CI, 22–48 days) and 61 days (95% CI, 7–115
days), respectively (Table 3).
Univariate analysis revealed that smoking history and
histology type were significant predictors of PFS, whereas
TABLE 2. Tumor Response According to Clinicopathologic
Factors
Variables
Response Rate Disease Control Rate
n/Total
(%) pa
n/Total
(%) pa
Total 20/74 (27.0) 35/74 (47.3)
Age (yr) 0.44 0.23
65 12/39 (30.8) 21/39 (53.8)
65 8/35 (22.9) 14/35 (40.0)
Gender 0.01 0.005
Female 15/38 (39.5) 24/38 (63.2)
Male 5/36 (13.9) 11/36 (30.6)
Smoking 0.001 0.001
Never 17/40 (42.5) 26/40 (65.0)
Ever 3/34 (8.8) 9/34 (26.5)
Stage 0.66 0.42
IIIB 1/7 (14.3) 2/7 (28.6)
IV 19/67 (28.4) 33/67 (49.3)
Histology 0.04 0.01
ADC 19/58 (32.8) 32/58 (55.2)
Non-ADC 1/16 (6.3) 3/16 (18.8)
a Tested by 2 test.
ADC, adenocarcinoma.
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age, gender, ECOG PS, and tumor stage were not. These two
predictor variables remained significant even in the multivar-
iate analysis of PFS using covariates of age, gender, smoking
history, and histology type (Table 4). The risk of progression
was significantly lower in never smokers (hazard ratio [HR],
0.46; 95% CI, 0.21–0.97; p  0.04) and in patients with
adenocarcinoma (HR, 0.50; 95% CI, 0.26–0.94; p  0.03)
compared with ever smokers and patients with nonadenocar-
cinoma, respectively.
The median OS was significantly longer in female
patients than in male patients (186 days; 95% CI, 60–312
days versus 29 days; 95% CI, 8.5–15.8 days; p  0.02) and
longer in never smokers than in ever smokers (159 days; 95%
CI, 20–298 days versus 37 days; 95% CI, 19–55 days; p 
0.005). However, gender and smoking history were not in-
dependent predictors of OS, as assessed by multivariate
analysis.
Safety and Tolerability
Treatment-related adverse effects were evaluated in 74
patients (Table 5). Serious treatment-related adverse effects
with grade 3 or more were observed in seven patients,
including pneumonitis (n  4), anorexia (n  2), nausea/
vomiting (n  1), and elevated liver enzymes (n  1).
Treatment-related death occurred in two patients because of
interstitial pneumonitis. The first patient was a 66-year-old
male patient who had previously suffered from interstitial
pulmonary fibrosis. The patient developed pneumonitis after
TABLE 3. Survival in Univariate Analysis
Variables
PFS OS
Median, d
(95% CI) HR (95% CI) pa
Median, d
(95% CI) HR (95% CI) pa
Total 32 (22–48) 61 (7–115)
Age (yr) 0.15 0.10
65 56 (20–92) 0.70 (0.43–1.14) 197 (95–299) 0.67 (0.41–1.09)
65 29 (13–49) 1.0 49 (43–55) 1.0
Gender 0.11 0.02
Female 57 (7–107) 0.68 (0.41–1.10) 186 (60–312) 0.65 (0.40–0.99)
Male 22 (11–33) 1.0 29 (6–52) 1.0
Smoking 0.01 0.005
Never 61 (17–105) 0.55 (0.34–0.89) 159 (20–298) 0.58 (0.35–0.94)
Ever 22 (11–33) 1.0 37 (19–55) 1.0
ECOG 0.52 0.35
3 45 (22–68) 0.85 (0.51–1.40) 83 (0–202) 0.69 (0.42–1.14)
4 22 (15–29) 1.0 48 (13–83) 1.0
Stage 0.07 0.50
IIIB 21 (3–39) 2.00 (0.90–4.47) 23 (20–26) 1.27 (0.57–2.81)
IV 38 (23–53) 1.0 68 (0–145) 1.0
Histology 0.007 0.32
ADC 45 (24–66) 0.46 (0.25–0.83) 68 (0–135) 0.73 (0.41–1.30)
Non-ADC 23 (11–35) 1.0 53 (12–82) 1.0
a Tested by the log rank test.
PFS, progression free survival; OS, overall survival; CI, confidential interval; HR, hazard ratio; ECOG, Eastern Cooperative Group;
ADC, adenocarcinoma.
TABLE 4. Survival in Multivariate Analysis
Variables
PFS OS
HR (95% CI) pa HR (95% CI) pa
Age (65 yr vs.
65 yr)
0.73 (0.44–1.21) 0.22 0.67 (0.40–1.11) 0.12
Gender (female vs.
male)
0.77 (0.34–1.69) 0.53 0.88 (0.41–1.86) 0.73
Smoking history
(never vs. ever)
0.46 (0.21–0.97) 0.04 0.64 (0.30–1.33) 0.23
Histology (ADC vs.
non-ADC)
0.50 (0.26–0.94) 0.03 0.91 (0.48–1.73) 0.78
a Tested in Cox regression model with age, gender, smoking history, and histology.
PFS, progression free survival; OS, overall survival; HR, hazard ratio; CI, confi-
dential interval.
TABLE 5. Treatment-Related Adverse Effects
Variables
Grade,a n (%)
0 1 2 3 4
Anorexia 58 (78.3) 7 (9.5) 7 (9.5) 2 (2.7) 0 (0.0)
Nausea/vomiting 55 (74.3) 15 (20.3) 3 (4.1) 1 (1.4) 0 (0.0)
Diarrhea 37 (50.0) 33 (44.6) 4 (5.4) 0 (0.0) 0 (0.0)
Skin rash 47 (63.5) 18 (24.3) 9 (12.1) 0 (0.0) 0 (0.0)
Pruritis 63 (85.1) 4 (5.4) 7 (9.5) 0 (0.0) 0 (0.0)
Pneumonitis 60 (81.1) 7 (9.5) 3 (4.1) 2 (2.7) 2 (2.7)
AST/ALT 63 (85.1) 9 (12.1) 1 (1.4) 1 (1.4) 0 (0.0)
a Assessed according to the National Cancer Institute Common Terminology
Criteria for Adverse Events, version 3.0.
AST, aspartate aminotransferase; ALT, alanine aminotransferase.
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day 35 of gefitinib treatment and died of respiratory failure.
The second patient, a 69-year-old male with massive tumor
burden on both lung fields, died of pneumonitis after day 15
of gefitinib treatment. All serious adverse events other than
elevated liver enzymes developed within the second cycle of
gefitinib administration.
Treatment Outcomes According to Favorable
Clinical Predictors
Table 6 lists the response rates in the subgroups clas-
sified according to the three clinical predictors (smoking
history, gender, and histology type). The group of never-
smoker females with adenocarcinoma showed response rate
of 50.0% (95% CI, 30.0–69.7%), whereas the remaining
groups had response rate of 13.0% (95% CI, 2.9–23.1%).
There was a significant difference in PFS (130 days [95% CI,
51–209 days] versus 23 days [95% CI, 16–30 days]; p 
0.006) and in OS (236 days [95% CI, 150–322 days] versus
48 days [95% CI, 27–69 days]; p  0.03) between never-
smoker females with adenocarcinoma and the other patients
(Figure 3).
DISCUSSION
In this study, patients treated with gefitinib showed
overall response rate of 27.0%, median PFS of 44 days, and
median OS of 61 days, consistent with the retrospective study
of Yang et al.,19 which showed that gefitinib treatment
FIGURE 3. Progression-free survival (PFS) curves (A) and overall survival (OS) curves (B) for the group of never-smoker fe-
males with adenocarcinoma (N-F-A) and for the other groups among patients with advanced non-small cell lung cancer
(NSCLC) with a poor performance status (PS) who were treated with first-line gefitinib. Survival difference was tested using
the log-rank test.
TABLE 6. Response Rates According to Three Favorable Clinical Predictors
Never Smoker Ever Smoker
Female Male Total Female Male Total
ADC 14/28 (50.0%) 2/5 (40.0%) 16/33 (48.5%) 0/4 (0.0%) 3/21 (14.3%) 3/25 (12.0%)
Non-ADC 1/5 (20.0%) 0/2 (0.0%) 1/7 (14.3%) 0/1 (0.0%) 0/8 (0.0%) 0/9 (0.0%)
Total 15/33 (45.5%) 2/7 (28.6%) 17/40 (42.5%) 0/5 (0.0%) 3/29 (10.3%) 3/34 (8.8%)
ADC, adenocarcinoma.
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yielded response rate of 28% and median OS of 2.4 months
in 76 Taiwan patients who had ECOG PS 3 or 4 without prior
chemotherapy. Among the various clinicopathological vari-
ables analyzed in this study, female gender, never-smoking
history, and adenocarcinoma histology were strong predictors
of tumor response or disease control with gefitinib, as de-
scribed in prior studies.5,6 A history of never smoking and
adenocarcinoma histology remained an independent predictor
of longer PFS in the multivariate analysis.
The subgroup of never-smoker females with adenocar-
cinoma showed a better tumor response and longer survival
time compared with the other groups. Although this group
had a poor PS of ECOG 3 or 4, its response rate of 50.0% was
comparable with that observed in the group with the same
characteristics but with a good PS of ECOG 0 to 2 (52.2%),
as reported previously by our group.20 Furthermore, this
group clearly showed improved survival (median PFS, 130
days; median OS, 236 days) compared with chemonaïve
patients with an ECOG PS of 2 or 3 who were given best
supportive care exclusively, as assessed in a randomized
prospective study (median PFS, 1.3 months; median OS, 2.7
months).9 Although we cannot completely exclude the effect
of the good prognostic aspect of these three clinical charac-
teristics,21–23 these survival differences observed for patients
with poor PS cannot be explained by intrinsic biologic fea-
tures only without the gefitinib treatment effect.
The response rate to gefitinib in the clinically selected
patients included in this study was numerically lower than
that detected in the genetically selected patients assessed in a
Japanese phase II study,10 although it is difficult to perform a
direct comparison between the studies. These differences
reflect the superiority of this genetic predictor over clinical
predictors in the identification of responders to gefitinib.
However, the technical feasibility of the genetic test should
be considered in clinical applications, together with the pre-
dictive accuracy. A mutational study is feasible only in a
small portion of patients with poor PS, because they are
vulnerable to complications associated with the invasive
procedures necessary for tissue sampling and do not have
sufficient time to delay treatment. Thus, it seems reasonable
to use clinical predictors for the selection of patients with
poor PS who would benefit from gefitinib treatment, espe-
cially in East Asian patients who are likely to harbor EGFR
mutations. In addition, it is necessary to identify potential
molecular markers in more easily accessible materials for
patients with poor PS, such as sputum or blood samples.
One major concern is that patients with poor PS may be
more prone to drug toxicity than are patients with good PS,
even in the case of targeted agents.24 A Japanese feasibility
study noted that gefitinib should be given with caution to
patients with an ECOG PS of 3 because of the high risk-to-
benefit ratio of this treatment.24 In this earlier study, grade 3
and 4 toxicity occurred in 5 (42%) of 12 patients, including 2
cases of pneumonitis. In our study, however, the incidence of
grade 3 to 4 treatment-related adverse events was similar to
that reported in previous studies involving patients with good
PS.11–14 The overall incidence of adverse events did not seem
to be increased in this study, although it is possible that not all
adverse events were captured because of the retrospective
nature of this study. Furthermore, two other prospective
studies of poor PS patients demonstrated that gefitinib can be
applied safely in this clinical setting.9,10 Based on its favor-
able safety profile and possible efficacy on East Asian de-
scent, the Korean-National Comprehensive Cancer Network
guideline (v.2.2008) recommends best supportive care or
EGFR tyrosine kinase inhibitors as first-line therapy for
patients with advanced NSCLC with ECOG PS 3 or 4.25
This study has several limitations. First, the validity of
the data presented is to some extent limited by the retrospec-
tive nature of the study. Second, there were inherent limita-
tions in collecting systematic toxicity data and also more
detailed information on quality of life parameters, which
would have been an important outcome measures in patients
with poor PS. Third, short-term assessment of tumor re-
sponses in clinically unstable patients with poor PS could
have adversely affected the PFS. Despite of these limitations,
however, there is no doubt that some patients benefited from
gefitinib monotherapy.
In conclusion, gefitinib monotherapy provided clinical
benefits in a selected group of chemonaïve patients with
NSCLC with poor PS of ECOG 3 or 4 who were unfit for
standard chemotherapy. In particular, three clinically favor-
able predictors of response (i.e., never-smoking history, fe-
male gender, and adenocarcinoma) may be useful for the
identification of subjects eligible for gefitinib treatment
among the patient population with poor PS.
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